Cargando…

Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial

INTRODUCTION: Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, showed deep, durable respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGarvey, November, Ung, Brian, Carattini, Thomas, Imanak, Ken, Lee, Abraham, Campbell, Timothy B., Patwardhan, Pallavi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499666/ https://www.ncbi.nlm.nih.gov/pubmed/37597153 http://dx.doi.org/10.1007/s12325-023-02623-w

Ejemplares similares

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
por: Jagannath, Sundar, et al.
Publicado: (2021)

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA
por: Piasecki, Julia, et al.
Publicado: (2023)

Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
por: Delforge, Michel, et al.
Publicado: (2022)

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023)

Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma
por: Connarn, Jamie N., et al.
Publicado: (2023)

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
por: Rodríguez-Otero, P., et al.
Publicado: (2023)

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
por: Logue, Jennifer M., et al.
Publicado: (2022)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
por: Oriol, Albert, et al.
Publicado: (2021)

S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS
por: Patel, Krina, et al.
Publicado: (2023)

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
por: Manier, Salomon, et al.
Publicado: (2023)

Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
por: Mann, Hashim, et al.
Publicado: (2022)

Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
por: Minakata, Daisuke, et al.
Publicado: (2023)

P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
por: Delforge, Michel, et al.
Publicado: (2023)

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
por: Lin, Yi, et al.
Publicado: (2023)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C
por: Alsina, Melissa, et al.
Publicado: (2023)

Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
por: Oswald, Laura B., et al.
Publicado: (2023)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
por: Sanoyan, Dilara Akhoundova, et al.
Publicado: (2023)

P867: TUMOR PROFILING OF IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) PATIENTS IN KARMMA SHOWED COMPARABLE RESPONSES IN EXISTING MOLECULAR HIGH-RISK SUBSETS AND PRELIMINARY GENE SIGNATURE OF DURABLE RESPONSE
por: Martin, N., et al.
Publicado: (2022)

P866: CORRELATIVE ANALYSIS TO DEFINE PATIENT PROFILES ASSOCIATED WITH MANUFACTURING AND CLINICAL ENDPOINTS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL (BB2121)
por: Rytlewski, J., et al.
Publicado: (2022)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
por: Mirza, Abu-Sayeef, et al.
Publicado: (2023)

P1740: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IDECABTAGENE VICLEUCEL VS BELANTAMAB MAFODOTIN: A MATCHING-ADJUSTED INDIRECT COMPARISON STUDY
por: Shah, N., et al.
Publicado: (2022)

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
por: Marquard, Franziska, et al.
Publicado: (2023)

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study
por: Terpos, Evangelos, et al.
Publicado: (2021)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Time duration and health care resource use during cancer diagnoses in the United States: A large claims database analysis
por: Gitlin, Matthew, et al.
Publicado: (2023)

Increased healthcare costs by later stage cancer diagnosis
por: McGarvey, November, et al.
Publicado: (2022)

MMA:DMA ratios reversed.
por: Slayton, T
Publicado: (1997)

Riding Kar9 into the bud
por: LeBrasseur, Nicole
Publicado: (2003)

Kar'ted to plus ends
por: LeBrasseur, Nicole
Publicado: (2006)

Uncommonly Missed Diagnosis of Methylmalonic Acidemia (MMA) in Adults and Usefulness of Testing for MMA in Cases of Seizures/Neuropathy/Weakness/Ataxia
por: Cocuzzo, Brianna, et al.
Publicado: (2023)

PS / Starting-up LET, HET, MMA
por: Boillot, J, et al.
Publicado: (1981)

Renal Growth in Isolated Methylmalonic Acidemia (MMA)
por: Kruszka, Paul S., et al.
Publicado: (2013)

Breast, Colorectal, Lung, Prostate, and Cervical Cancer Screening Prevalence in a Large Commercial and Medicare Advantage Plan, 2008–2020
por: Kim, Ashley, et al.
Publicado: (2022)

P809: BASELINE CHARACTERISTICS IDENTIFYING PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICELEUCEL (IDE-CEL; BB2121) WHO ARE AT RISK FOR SEVERE/REFRACTORY INFLAMMATORY ADVERSE EVENTS
por: Mashadi-Hossein, Afshin, et al.
Publicado: (2023)

Inhibition Gets a New KAR Smell
por: Courtney, Connor D., et al.
Publicado: (2019)

Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency
por: Almási, Tímea, et al.
Publicado: (2019)

P1410: EFFICACY OBSERVATION OF A SECOND INFUSION OF BCMA-CAR-T CELLS IN PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA
por: Wang, Yi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5s37mtbotq9ro8v4jqn094cdpa